Diane Xavier de Ávila

Diane Xavier de Ávila

Auto-generated profile, based on publicly available information

Diane Xavier de Ávila

Universidade Federal Fluminense, Brasil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
MSMarcus V. Simões
Marcus V. Simões
FFFabio Fernandes
Fabio Fernandes
FMFabiana Marcondes-Braga
Fabiana Marcondes-Braga
PSPhilip Scheinberg
Philip Scheinberg
ECEdileide de Barros Correia
Edileide de Barros Correia
EMEvandro Tinoco Mesquita
Evandro Tinoco Mesquita
1. Introdução Nos últimos anos, foram consolidados avanços expressivos no conhecimento de amiloidose cardíaca (AC), trazendo uma profunda reformulação do seu significado clínico. Além de haver evidências convincentes de que AC seja uma causa relativamente comum de insuficiência cardíaca com fração de ejeção preservada (ICFEP), assistimos o surgimento de terapias específicas modificadoras do curso natural da doença, capazes de prolongar a sobrevida dos pacientes acometidos. Em paralelo, relevantes progressos nas técnicas de imagem cardiovascular têm contribuído grandemente para o reconhecimento [...] 1. Introdução Nos últimos anos, foram consolidados avanços expressivos no conhecimento de amiloidose cardíaca (AC), trazendo uma profunda reformulação do seu significado clínico. Além de haver evidências convincentes de que AC seja uma causa relativamente comum de insuficiência cardíaca com fração de ejeção preservada (ICFEP), assistimos o surgimento de terapias específicas modificadoras do curso natural da doença, capazes de prolongar a sobrevida dos pacientes acometidos. Em paralelo, relevantes progressos nas técnicas de imagem cardiovascular têm contribuído grandemente para o reconhecimento

1 January 2022 in Current Cardiology Reviews
Verified
Journal Article
Closed access
PDF file
DÁDiane Xavier de Ávila
Diane Xavier de Ávila
HVHumberto Villacorta
Humberto Villacorta
WMWolney de Andrade Martins
Wolney de Andrade Martins
EMEvandro Tinoco Mesquita
Evandro Tinoco Mesquita
Introduction: The knowledge on High-Output Cardiac Failure (HOCF) has greatly improved in the last two decades. One of the advances was the identification of a new phenotype of HOCF, characterized by the absence of ventricular dilation, already associated with liver disease, Arteriovenous Fistulas (AVF), lung disease, myelodysplastic syndromes, and obesity. However, it has been noted that any aetiology can present with one of the two phenotypes, depending on the evolution. Objective: The study aims to describe, through an integrative review, the physiopathology and aetiologies of HOCF and to discuss phenotypes associated with this condition. Methods: Revisions, guidelines, case-controls, cohort studies and clinical studies were searched in MEDLINE and LILACS, using the connectives in the “cardiac output, high” database (MeSH Terms) OR “high cardiac output” (All Fields). Discussion: Two distinct phenotypes are currently described in the HOCF, regardless of the aetiology: 1) one with enlarged cardiac chambers; and 2) with normal heart chambers. The mechanisms related to HOCF are vasodilation, arteriovenous shunts that cause increased microvascular density, Reduced Systemic Vascular Resistance (RSVR), and high metabolism. These mechanisms lead to activation of the renin-angiotensin-aldosterone system, sodium and water retention, activation of neprilysin, of the sodium-glucose-2 transporter, which promote interstitial fibrosis, ventricular remodeling and a consequent increase in cardiac output >8L/min. Conclusion: Many aetiologies of HOCF have been described, and some of them are potentially curable. Prompt recognition of this condition and proper treatment may lead to better outcomes.

3 October 2022 in Revista Portuguesa de Cardiologia
Verified
Journal Article
Open access
FRFelipe Mafort Rohen
Felipe Mafort Rohen
DÁDiane Xavier de Ávila
Diane Xavier de Ávila
CLCarolina Martins Cabrita Lemos
Carolina Martins Cabrita Lemos
RSRicardo Santos
Ricardo Santos
MRMário Ribeiro
Mário Ribeiro
HVHumberto Villacorta
Humberto Villacorta
The MAGGIC risk score has been validated to predict mortality in patients with heart failure (HF). To assess the score ability to predict hospitalization and death and to compare with natriuretic peptides. Ninety-three consecutive patients (mean age 62±10 years) with chronic HF and left ventricular ejection fraction (EF) 1000 pg/mL (p=0.014) and the MAGGIC score (p=0.025) were independently associated with the primary outcome. The MAGGIC risk score was an independent predictor of events, including heart failure hospitalization. The addition of biomarkers improved the accuracy of the score.

1 March 2025 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
GMGustavo Rodolfo Moreira
Gustavo Rodolfo Moreira
DÁDiane Xavier Ávila
Diane Xavier Ávila
ACAngelo Michele Di Candia
Angelo Michele Di Candia
VSVictoria Depes Scaramussa
Victoria Depes Scaramussa
HVHumberto Villacorta
Humberto Villacorta
Background There is a lack in identifying heart failure (HF) patients with an increased risk of hospitalization and death. Growth differentiation factor 15 (GDF-15), a biomarker associated with inflammation and oxidative stress, emerges as a candidate associated with cardiovascular and renal disease. The low estimated glomerular filter rate (eGFR), low urinary sodium (UNa), and the high ratio of albumin to creatinine are renal markers already associated with a high risk of hospitalization and mortality. Objective To evaluate the relationship between GDF-15 and renal markers in patients with chronic HF. Method We enrolled 87 consecutive patients with symptomatic HF with reduced left ventricular ejection fraction (LVEF < 40%), mildly reduced LVEF (40–49%) or an improved LVEF (50% but previously < 50%) in a university hospital. We compared the associations of GDF-15 and NT-proBNP with renal markers using correlation tests and multiple regression analysis at the significance level of 5%. Results GDF-15 and NT-proBNP had weak to moderate negative correlations with UNa (r=-0.362, p=0.007; r=-0.334, p=0.014, respectively) and eGFR (r=-0.385, p=0.0002; r=-0.346, p=0.001, respectively). GDF-15, age, hypertension and NT-proBNP were independently associated with eGFR in multiple regression analysis (overall R2=0.32). GDF-15 (positive) and age (negative) were independently associated with UAC (overall, R2=0.30). Only GDF-15 was independently associated with UNa (R2=0.45). Conclusions In these chronic patients with HF, GDF-15 is better correlated with markers of renal dysfunction than NT-proBNP. Since the prognostic value of renal markers is well established, these findings reinforce the prognostic role of GDF-15 in chronic HF.

1 January 2019 in International Journal of Cardiovascular Sciences
Verified
Journal Article
Open access
DÁDiane Xavier Ávila
Diane Xavier Ávila
PMPriscila Abreu Matos
Priscila Abreu Matos
GQGabriel Quintino
Gabriel Quintino
WMWolney de Andrade Martins
Wolney de Andrade Martins
DMDalmo Machado
Dalmo Machado
HVHumberto Villacorta
Humberto Villacorta

20 October 2025 in ABC Heart Failure & Cardiomyopathy
Verified
Journal Article
Open access
PDF file
FNFrank Nunes
Frank Nunes
RCRaquel Germer Toja Couto
Raquel Germer Toja Couto
DADiane Xavier de Avila
Diane Xavier de Avila
ATAna Flavia Malheiros Torbey
Ana Flavia Malheiros Torbey
KLKárila Scarduelli Luciano
Kárila Scarduelli Luciano
EMEvandro Tinoco Mesquita
Evandro Tinoco Mesquita
Filamin C is an essential protein for the integrity of the sarcomere and cytoskeleton of cardiomyocytes. Pathogenic variants in the FLNC gene are associated with a wide range of cardiomyopathies and may present distinct phenotypes depending on the type of genetic alteration. Truncated variants are frequently associated with dilated and arrhythmogenic cardiomyopathy, while missense variants are more related to hypertrophic and restrictive forms. These phenotypic differences reflect the molecular and structural impact of the FLNC variant on filamin C [...] Abstract Filamin C is an essential protein for the integrity of the sarcomere and cytoskeleton of cardiomyocytes. Pathogenic variants in the FLNC gene are associated with a wide range of cardiomyopathies and may present distinct phenotypes depending on the type of genetic alteration. Truncated variants are frequently associated with dilated and arrhythmogenic cardiomyopathy, while missense variants are more related to hypertrophic and restrictive forms. These phenotypic differences reflect the molecular and structural impact of the FLNC variant on filamin C